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Purpose: Celastrol, a traditional Chinese medicine, is widely used in anti-inflammation and 
anti-angiogenesis research. However, the poor water solubility of celastrol restricts its further 
application. This paper aims to study the effect of celastrol nanoparticles (CNPs) on corneal 
neovascularization (CNV) and determine the possible mechanism.
Methods: To improve the hydrophilicity of celastrol, celastrol-loaded poly(ethylene glycol)-
block-poly(ε-caprolactone) nanopolymeric micelles were developed. The characterization of 
CNPs was measured by dynamic light scattering and transmission electron microscopy analysis. 
Celastrol loading content and release were assessed by ultraviolet-visible analysis and high 
performance liquid chromatography, respectively. In vitro, human umbilical vein endothelial 
cell proliferation and capillary-like tube formation were assayed. In vivo, suture-induced CNV 
was chosen to evaluate the effect of CNPs on CNV in rats. Immunohistochemistry for CD68 
assessed the macrophage infiltration of the cornea on day 6 after surgery. Real-time quan-
titative reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent 
assay were used to evaluate the messenger ribonucleic acid and protein levels, respectively, of 
vascular endothelial growth factor, matrix metalloproteinase 9, and monocyte chemoattractant 
protein 1 in the cornea.
Results: The mean diameter of CNPs with spherical shape was 48 nm. The celastrol loading 
content was 7.36%. The release behavior of CNPs in buffered solution (pH 7.4) showed a 
typical two-phase release profile. CNPs inhibited the proliferation of human umbilical vein 
endothelial cells in a dose-independent manner and suppressed the capillary structure formation. 
After treatment with CNPs, the length and area of CNV reduced from 1.16 ± 0.18 mm to 
0.49 ± 0.12 mm and from 7.71 ± 0.94 mm2 to 2.29 ± 0.61 mm2, respectively. Macrophage 
infiltration decreased significantly in the CNP-treated corneas. CNPs reduced the expression of 
vascular endothelial growth factor, matrix metalloproteinase 9, and monocyte chemoattractant 
protein 1 in the cornea on day 6 after suturing.
Conclusion: CNPs significantly inhibited suture-induced CNV by suppressing macrophage 
infiltration and the expression of vascular endothelial growth factor and matrix metalloprotei-
nase 9 in the rat cornea.
Keywords: celastrol, PEG-b-PCL nanopolymeric micelles, corneal neovascularization, 
  macrophages, VEGF, MMP-9
Introduction
Corneal neovascularization (CNV) is a leading aspect of the pathogenesis of many 
sight-threatening disorders, such as corneal graft rejection, corneal chemical injury, and 
infection.1,2 The process of new blood vessel formation requires proliferation, migration, 
and capillary tube formation by endothelial cells.3,4 The infiltration of   inflammatory 
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cells and the release of several angiogenesis-related media-
tors contribute to multiple aspects of CNV .5,6 CNV is also 
controlled by the interaction of endothelial cells with the 
extracellular matrix and the balance between proangiogenic 
and anti-angiogenic mediators. An imbalance toward proan-
giogenic factors, such as vascular endothelial growth factor 
(VEGF), tumor necrosis factor-α (TNF-α), and matrix metal-
loproteinases (MMPs), can upregulate angiogenesis.7
Macrophages play major roles in many angiogenesis 
models by secreting several inflammatory and angiogenic 
mediators.8–10 Macrophage infiltration promotes suture-
induced CNV .11 The authors’ previous unpublished studies 
showed that macrophages can induce CNV by upregulating 
VEGF and MMP-9.
Celastrol, also known as tripterine, is a traditional Chinese 
herb derived from Trypterygium wilfordii.12 Celastrol exhibits 
potent anti-angiogenic and anti-inflammatory activities by 
modulating multiple pro-angiogenic and pro-inflammatory 
cytokines, such as hypoxia-inducible factor-1α, TNF-α, 
VEGF, and cyclooxygenase 2.13–15 These mediators play 
major roles in the proliferation of endothelial cells and the 
progression of angiogenesis. In macrophages, celastrol 
also inhibits lipopolysaccharide- and interferon-γ-induced 
production of TNF-α, nitric oxide, interleukin-1β (IL-1β), 
prostaglandin E2, and IL-6.16–19 Although celastrol has shown 
potent anti-inflammatory and anti-angiogenic activities in 
many models, it is unknown whether celastrol can modulate 
CNV and inflammation.
Despite the powerful beneficial bioactivity of celastrol, 
its clinical use has been limited mainly due to its poor water 
solubility. Therefore, it will be necessary to improve its water 
solubility while still retaining its activities in order to develop 
new celastrol-based therapeutics. Nanoformulated poly(ethylene 
glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) micelles 
have shown promise in improving the hydrophilicity of drugs 
and enabling their extended release.20,21
The aim of the present study was to determine the effects 
of celastrol-loaded PEG-b-PCL nanopolymeric micelles on 
corneal angiogenesis induced by suturing in the rat cornea 
and to determine the possible mechanism involved.
Materials and methods
Preparation of celastrol-loaded polymer 
micelles
Chinese herbal celastrol (Figure 1A) was purchased from 
the Shanghai Institute of Materia Medica, Chinese Academy 
of Sciences (Shanghai, China). Celastrol-loaded PEG-b-
PCL micelles were prepared by dissolving PEG-b-PCL 
(2000:1000, weight-average molecular weight/number aver-
age molecular weight: 1.18; JCS Biopolytech Inc, Toronto, 
ON, Canada; Figure 1B) (10 mg) and celastrol (2 mg) in 
chloroform (2 mL) and adding this solution dropwise to 
double-distilled water (20 mL) under ultrasonic agitation 
using a sonic dismembrator (model 60; Thermo Fisher 
  Scientific, Pittsburgh, PA) at a power level of 30. The organic 
solvent was then removed by vacuum distillation using a 
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Figure 1 The structure of (A) celastrol and (B) poly(ethylene glycol)-block-poly(ε-caprolactone) nanopolymeric micelles and (C) schematic illustration of celastrol-loaded 
micelle formation.
Abbreviation: PEG-b-PCL, poly(ethylene glycol)-block-poly(ε-caprolactone).
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rotary evaporator to allow micelle formation. The samples 
were further concentrated and washed three times to remove 
insoluble material and unincorporated drug through a 
0.22 µm polyethersulfone filter. A schematic illustration of 
celastrol-loaded micelle formation is shown in Figure 1C.
Determination of nanopolymeric  
micelle diameters
The particle size of nanopolymeric micelles was measured 
by dynamic light scattering. The suspension was exam-
ined at 25°C on 90Plus/BI-MAS equipment (Brookhaven 
  Instruments Corporation, Holtsville, NY). The related data 
were collected by an autocorrelator with a detection angle 
of scattered light of 90°.
Transmission electron microscopy  
(TEM) analysis
The celastrol-loaded nanopolymeric micelles were character-
ized using TEM. Samples for TEM analysis were prepared 
on copper grids coated with amorphous carbon. A small drop 
of uranyl acetate solution (2% weight/volume in water) was 
added to the copper grid for negative staining of samples, 
and the grid was blotted with filter paper after 1 minute. TEM 
measurements were performed on an H-7650 TEM (Hitachi 
High Technologies, Tokyo, Japan) operated at 80 kV .
Evaluation of celastrol loading content
The celastrol loading content, defined as the weight percentage 
of celastrol in micelle, was quantified by ultraviolet-visible 
analysis using an ultraviolet-visible spectrophotometer 
(UV-2000; Unico Instruments Co, Ltd, Shanghai, China). 
First, celastrol-loaded micelle solutions were frozen and lyo-
philized to yield the solid micelle samples. And then the dried 
micelle samples were weighed and redissolved in a mixture 
of dimethyl sulfoxide and chloroform (1:1, volume/volume) 
for the ultraviolet-visible measurement. Celastrol solutions of 
various concentrations were prepared, and the absorbance at 
425 nm was measured to generate a calibration curve for the 
celastrol loading content calculations from micelles.
In vitro release of celastrol from polymer 
micelles
Freeze-dried micelle samples (12 mg each) were resus-
pended in 3 mL phosphate buffered saline (pH 7.4) and 
then transferred into a dialysis bag (molecular weight 
cut-off: 14,000 Da). The bag was placed into the same 
buffered solution (50 mL). Release study was performed 
at 37°C in an incubator shaker (C24; New Brunswick 
  Scientific, Enfield, CT). At selected time intervals, buffered 
solution outside the dialysis bag was removed for reverse-
phase high performance liquid chromatography (Dionex 
UltiMate®; Thermo Fisher; 5 µm, 4.6 × 250 mm columns) 
analysis and replaced with fresh buffer solution. Celastrol 
concentration was calculated based on the absorbance inten-
sity at 425 nm. In the assessment of drug release behavior, 
the cumulative amount of released drug was calculated and 
the percentage of drug released from micelles was plotted 
against time.
Cell culture
The human umbilical vein endothelial cells (HUVECs) (EA.
hy 926; American Type Culture Collection, Manassas, VA) 
were cultured as described previously.22 Briefly, cells were 
grown in Gibco® Dulbecco’s modified Eagle’s medium (with 
4.5 g/mL glucose; Invitrogen Life Technologies, Carlsbad, 
CA) supplemented with Gibco® 10% fetal bovine serum 
(Invitrogen) at 37°C in a 5% carbon dioxide atmosphere.
In vitro hUVEC proliferation assays
Inhibitory effects of celastrol particles on HUVEC prolif-
eration were measured using a water-soluble tetrazolium 
salt (WST) reagent (2-[2-methoxy-4-nitrophenyl]-
3-[4-nitrophenyl]-5-[2,4-disulfophenyl]-2H, WST-8; Nacalai 
Tesque Inc, Kyoto, Japan) according to the manufacturer’s 
protocol. EA.hy 926 cells were plated at a density of 2 × 103 
per well in triplicate in fresh medium. After 24 hours, cells 
were respectively treated with medium containing different 
concentrations of celastrol nanoparticles (CNPs) (0, 1.7, 
3.4, 6.8, 13.6, or 27.2 µg/mL; celastrol loading content: 
7.36%) and the same dosage of PEG-b-PCL micelles without 
celastrol, and then cultured for an additional 72 hours. This 
treatment was followed by the addition of 10 µL of WST 
solution to each well, and the cells were incubated for 4 hours 
at 37°C. The absorbance was measured at 450 nm. Changes 
in cell morphology were captured after 72 hours of treatment 
with CNPs. The antiproliferation effect of free celastrol – 
dissolved in dimethyl sulfoxide (0.2% volume/volume) – on 
HUVECs (0, 0.125, 0.25, 0.5, 1, or 2 µg/mL concentration) 
was also assessed to compare with the effect of CNPs. The 
measurement protocol was as described above.
Capillary-like tube formation assay
Tube formation was evaluated as described previously.23,24 
Briefly, the stock solution of Matrigel™ (BD Biosciences, 
San Jose, CA) was diluted 1:3 with Dulbecco’s modified 
Eagle’s medium, and 50 µL of diluted Matrigel solution 
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was then added into each well of an ice-cold 96-well 
plate. The plates were incubated at 37°C for 30 minutes to 
convert this into a gelatinous layer. EA.hy 926 cells were 
pretreated with a dilution of CNPs (13.6 µg/mL or 27.2 µg/
mL; celastrol loading content: 7.36%) for 30 minutes 
and then seeded onto the Matrigel layers in the 96-well 
plate at a density of 5 × 104 cells/well. After 10 hours, the 
tubular structure of endothelial cells was observed under 
an inverted microscope (magnification: ×200; Olympus 
Corporation, Tokyo, Japan). Three independent experi-
ments were performed.
Animal treatment
To clarify the effects of CNPs on CNV, the modified 
model of suture-induced CNV was used, as described 
previously.25,26 Before surgery, all female Sprague-Dawley 
rats (weighing 200–220 g) were deeply anesthetized. CNV 
was induced by suturing (two stitches) the temporal cornea 
with 10-0 nylon (Alcon Laboratories, Inc, Fort Worth, 
TX). The distance between the stitches and the limbus 
was approximately 1.5 mm. There was a distance of 1 mm 
between the two stitches. Tobramycin ointment was applied 
to the cornea to prevent corneal inflammation. To examine 
the anti-angiogenic activity of celastrol, 0.1 mL CNPs were 
administrated by subconjunctival injection at a concentra-
tion of 5.44 mg/mL (celastrol loading content: 7.36%) 
for each rat on day 0 and day 3 after surgery. The control 
group was exposed to the same dosage of blank PEG-b-
PCL micelles without celastrol. CNV was observed by 
slit-lamp microscopy (SL120; Carl Zeiss AG, Oberkochen, 
Germany) every day until day 6. Eye irritation was recorded 
according to the Draize eye test.27 The doses and time points 
used were based on the results of the authors’ unpublished 
observations.
Quantification of CNV
CNV was quantified according to a previous report.28 
Briefly, on the sixth postoperative day, the rats were anes-
thetized again with sodium pentobarbital (50 mg/kg body 
weight, intraperitoneally) and administered heparin at a 
dose of 2000 units/kg body weight via tail vein injection 
to prevent blood clotting. Thirty minutes after infusion, 
all rats were perfused with 10 mL of Higgins waterproof 
India ink (Sanford, Oak Brook, IL) through the thoracic 
aorta to visualize corneal vessels. The eyes were enucle-
ated and fixed in 10% neutralized buffered formaldehyde 
for 24 hours, and then the corneas were dissected and 
mounted on slides.
Corneal images were captured and analyzed with a slit-
lamp microscope (Carl Zeiss SL120) by an investigator who 
was blinded to the treatment assignment. The length and area 
of CNV were measured with Image-Pro® Plus 5.1 (Media 
Cybernetics Inc, Bethesda, MD), according to a previous 
report.28
histology and immunohistochemistry
Six days after surgery, the eyes were enucleated, fixed in 
10% neutralized buffered formaldehyde and embedded in 
paraffin. Thereafter, the tissue was cut into 5-µm thick sec-
tions and stained with hematoxylin and eosin. To identify 
infiltrating macrophages, immunohistochemistry for CD68 
(Santa Cruz Biotechnology, Santa Cruz, CA) was carried 
out on deparaffinized sections. Corneal morphology and 
images of the infiltrated macrophages were assessed by light 
  microscopy. The number of infiltrated macrophage (CD68+) 
cells in the corneal stroma was counted in five randomly 
selected fields (×400) of the immunofluorescence-stained 
slides by an experienced and independent cell scientist who 
was blinded to the treatment assignment.
Real-time quantitative reverse 
transcription-polymerase chain  
reaction (PCR)
Corneas were harvested on day 6 after surgery. Total 
ribonucleic acid (RNA) was isolated with TRIzol® reagent 
(Invitrogen), according to the manufacturer’s instructions. 
It was extracted with chloroform and proazamine, and tran-
scribed into complementary DNA using the Superscript™ 
First-strand Synthesis System for Reverse Transcription-PCR 
(Invitrogen), according to the manufacturer’s instructions. 
Quantitative real-time PCR was carried out using a 7100 Real-
Time PCR System (Applied Biosystems, Foster City, CA) 
with SYBR-Green 1 (Takara Bio Inc, Otsu, Japan) and ana-
lyzed with the ABI PRISM® 7000 Sequence Detection   System 
(Applied Biosystems). The primers used were as follows: 
VEGF, 5′-GTCCTCACTTGGATCCCGACA-3′ (forward) 
and 5′-CCTGGCAGGCAAACAGACTTC-3′ (reverse); 
MMP-9: 5′-AGCCGGGAACGTATCTGGA-3′ (forward) 
and 5′-TGGAAACTCACACGCCAGAAG-3′ (reverse); 
monocyte  chemoattractant  protein  1  (MCP-1): 
5′-CTATGCAGGTCTCTGTCACGCTTC-3′ (forward) 
and 5′-CAGCCGACTCATTGGGATCA-3′ (reverse); 
and β-actin: 5′-GGAGATTACTGCCCTGGCTCCTA-3′ 
(forward) and 5′-GACTCATCGTACTCCTGCTTGCTG-3′ 
(reverse). All expression levels were normalized to β-actin 
in the normal corneas.
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Enzyme-linked immunosorbent  
assay (ELISA)
VEGF, MMP-9, and MCP-1 concentrations in the cornea 
were determined using specific ELISA kits (R&D Systems 
Inc, Minneapolis, MN), according to the manufacturer’s 
instructions. On day 6 after surgery, the corneal tissues 
were collected in two groups. The proteins were extracted 
and stored at −80°C until assaying for VEGF, MMP-9, and 
MCP-1.
Statistical analysis
Statistical analysis was performed using IBM SPSS software 
for Windows (v 16.0; SPSS Inc, Chicago, IL). All data 
are presented as mean ± standard deviation. Differences 
between experimental and control groups were analyzed by 
independent-sample Student’s t-test. P values ,0.05 were 
considered statistically significant.
Results
The aim of this study was to investigate whether CNPs 
can suppress corneal angiogenesis and, if so, through what 
mechanism. To answer these questions, several in vitro and 
in vivo assays were used, including an analysis of corneal 
angiogenesis in vivo and an analysis of cell proliferation, 
cytotoxicity, and cellular morphology of HUVECs in vitro.
Characterization of celastrol-loaded  
nanopolymeric micelles and celastrol  
loading content
Celastrol-loaded PEG-b-PCL micelles were characterized 
before analyzing the anti-angiogenic effect of celastrol. 
The size and shape of the celastrol-loaded PEG-b-PCL 
micelles were determined by dynamic light scattering and 
TEM, respectively. From the dynamic light scattering data 
presented in Figure 2A, the mean diameter of blank and 
celastrol-loaded nanopolymeric micelles was 36 nm and 
48 nm, respectively. The electron photomicrograph of the 
nanopolymeric micelles shown in Figure 2B illustrates 
their spherical shape. TEM also confirmed their diameter 
at approximately 48 nm. The celastrol loading content of 
PEG-b-PCL micelle was 7.36%.
In vitro celastrol release study
The in vitro release behavior of celastrol-loaded micelles 
in buffered solutions (pH 7.4) was studied. As shown in 
Figure 3, a typical two-phase release profile was observed. 
That is, a relatively rapid release in the first stage followed 
by a sustained and slow release over a prolonged time of up 
to several weeks.
CNPs inhibit the growth and capillary 
structure formation of hUVECs
The effect of CNPs on the growth viability of HUVECs was 
investigated using WST assays. The morphologic changes of 
cells showed that increasing the amount of CNPs decreased 
the number of HUVECs (Figure 4A). CNPs reduced the 
viability of EA.hy 926 cells in a dose-dependent manner. 
At 6.8 µg/mL, 13.6 µg/mL, and 27.2 µg/mL CNP concen-
tration, the viability of EA.hy 926 cells was reduced signifi-
cantly (Figure 4B). However, the blank micelles showed no 
obvious toxicity on HUVECs in the tested concentration 
range and time (Figure 4B). The half maximal inhibitory 
concentration (IC50) value of the antiproliferation effect 
of CNPs at 72 hours was 6.875 µg/mL (celastrol loading 
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Figure 2 Average diameter of micelles before and after celastrol loading and transmission electron microscopy images of celastrol-loaded micelles. The particle size of 
nanopolymeric micelles was measured by dynamic light scattering. (A) Dynamic light scattering histogram reveals the size distribution of 48 nm celastrol polymeric micelles 
based on a poly(ethylene glycol)-block-poly(ε-caprolactone) copolymer (mean diameter: 36 nm). The celastrol nanoparticles were characterized using transmission electron 
microscopy. (B) Transmission electron microscopy image of the micelle sample after negative staining with 2% uranyl acetate solution shows their spherical shape.
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(Figure 5E and F). No eye irritation, corneal epithelial defect, 
or other adverse complications related to the topical CNPs 
were observed in any of the tested animals.
Celastrol nanopolymeric micelles inhibit 
neovascularization and macrophage 
infiltration in the rat cornea
Histologic analysis of the cornea revealed that CNP treatment 
led to a significant reduction in the number of infiltrating 
inflammatory cells in the treated group when compared 
with the control group. New blood vessels were inhibited 
and corneal edema was also distinctly mitigated by celastrol 
 ( Figure 6A and B). The number of infiltrating macrophages 
was significantly reduced in the cornea on day 6 after 
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Figure  4  Celastrol  nanoparticles  dose-dependently  inhibit  the  growth  and 
capillary structure formation of human umbilical vein endothelial cells (EA.hy 926). 
(A) Morphological variations of EA.hy 926 cells treated with celastrol nanoparticles 
(0, 1.7, 3.4, 6.8, 13.6, or 27.2 µg/mL) for 72 hours. (B) EA.hy 926 cells treated with 
either celastrol nanoparticles or blank micelles (0, 1.7, 3.4, 6.8, 13.6, or 27.2 µg/mL) 
for 72 hours. Water-soluble tetrazolium salt assay was used to determine cell viability 
after exposure to the nanoparticles. The blank micelles without celastrol showed a 
cell viability of above 95%. Increasing the amount of celastrol nanoparticles increased 
the inhibition effect on the EA.hy 926 cells. (C) Celastrol nanoparticles inhibited the 
tube formation of endothelial cells in Matrigel™ (BD Biosciences, San Jose, CA). 
EA.hy 926 cells pretreated with or without celastrol nanoparticles were placed in a 
96-well plate coated with Matrigel (5 × 104 cells per well). After 10 hours, the tubular 
structure of the endothelial cells was photographed (magnification: ×200).
Notes: The data are presented as mean ± standard deviation for three independent 
experiments  performed  in  triplicate.  Statistical  significance  was  based  on  the 
difference when compared with the control; *P , 0.01.
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Figure 3 In vitro drug release profiles of celastrol from poly(ethylene glycol)-
block-poly(ε-caprolactone) micelles (celastrol loading content: 7.36%) in phosphate 
buffered saline (ph 7.4) at 37°C. A typical two-phase release profile contained a 
burst release in the first stage followed by a sustained and slow release over a 
prolonged time of up to several weeks.
Note: The data are presented as mean ± standard deviation (n = 3).
  content: 7.36%). And the IC50 value of free celastrol on EA.hy 
926 cells was 0.325 µg/mL.
To further characterize the effect of celastrol on angiogen-
esis, an analysis of how celastrol regulates capillary tubule 
formation in HUVECs was done. When EA.hy 926 cells 
were seeded on Matrigel, tubular-like structures formed. 
However, treatment with 13.6 µg/mL or 27.2 µg/mL (celas-
trol loading content: 7.36%) of CNPs abolished the tubule 
formation (Figure 4C).
CNPs suppress corneal angiogenesis  
in a rat model
To investigate the effect of CNPs on CNV in vivo, 0.1 mL 
of CNPs by subconjunctival injection was administered at a 
concentration of 5.44 mg/mL on day 0 and day 3 after suture 
surgery in a rat model. New blood vessel buds appeared 
and began to develop into the corneal suture on day 1 or 2 
after surgery. Abundant CNV reached its peak on day 6 and 
began to regress after day 8 in the control group. Corneal 
edema was observed during neovascularization (Figure 5A). 
However, shorter and fewer new corneal vessels and sub-
stantially less edema were found in the celastrol-treated 
group (Figure 5B). Corneal angiogenesis produced a black 
color after ink perfusion on day 6 in both groups (Figure 5C 
and D). Administration of 0.544 mg of CNPs reduced the 
length and area of CNV . The average length and area were 
1.16 ± 0.18 mm and 7.71 ± 0.94 mm2, respectively, in the con-
trol group on day 6 after surgery, whereas the average length 
and area in the celastrol group decreased to 0.49 ± 0.12 mm 
and 2.29 ± 0.61 mm2, respectively (both P values ,0.001) 
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  surgery in the celastrol group compared to the control group 
(P , 0.001; Figure 6C–E). Histopathological evaluation was 
performed three times for six sections of each group.
CNPs decrease angiogenesis-related 
factor messenger RNA (mRNA) levels  
in the cornea
To further study the effect of CNPs on CNV , quantita-
tive real-time reverse transcription-PCR was performed to 
determine the relative mRNA expression of VEGF, MMP-9, 
and MCP-1 on day 6 after surgery in rat corneas. Normal 
corneas were used as the control. The mRNA expression of 
the normal corneas was arbitrarily set as 1.0. As shown in 
Figure 7, CNPs significantly decreased the mRNA expression 
of VEGF, MMP-9, and MCP-1 in the cornea (P , 0.001). 
When compared with the control, a significant decrease in 
the expressions of VEGF (5.89-fold versus 1.69-fold) and 
MCP-1 (10.11-fold versus 3.90-fold) and a moderate decrease 
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Figure 5 Inhibitory effects of celastrol nanoparticles on suture-induced corneal neovascularization in rats. Animals were sutured (two stitches) in the temporal cornea, and 
then treated with subconjunctival injection of celastrol nanoparticles (0.544 mg per rat) on day 0 and day 3 after surgery. Slit-lamp microphotographs of corneas were taken 
after mydriasis on day 6 after surgery. The pictures show (A) an intensive corneal neovascularization in response to suturing and (B) a marked inhibition of neovascularization 
by celastrol nanoparticles. The images were taken by perfusing the cornea with India ink on day 6 after suturing. Note the distinct suppression of corneal neovascularization by 
celastrol nanoparticles. (C) Abundant corneal neovascularization reached the sutures. (D) Shorter and fewer areas of corneal neovascularization were found in the celastrol-
treated group. (E and F) show the inhibition effect of celastrol nanoparticles on the length and area of corneal neovascularization, respectively.
Notes: The length and area of corneal neovascularization were measured with Image-Pro® Plus 5.1 (Media Cybernetics Inc, Bethesda, MD) in triplicate for each cornea. 
The data are presented as mean ± standard deviation of five rats. *P , 0.001 versus the control group (magnification: ×25).
Abbreviations: CI, confidence interval; CNPs, celastrol nanoparticles.
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Figure 6 Celastrol nanoparticles inhibit neovascularization and macrophage infiltration in rat cornea. Rats were treated with celastrol nanoparticles (0.544 mg per rat) 
on day 0 and day 3 after surgery. Corneal tissue was fixed in 10% neutralized buffered formaldehyde, and 5 µm paraffin sections were stained with hematoxylin and eosin. 
(A) Celastrol nanoparticle-treated group showed significantly inhibited neovascularization and inflammatory cell infiltration in cornea on day 6 after surgery when compared 
with (B) the control group. Red arrows show new blood vessels. Corneal sections were processed by anti-rat CD68 staining in (C) celastrol nanoparticle-treated group and 
(D) the control group. Celastrol nanoparticles suppressed macrophage infiltration in the cornea on day 6 after surgery. The number of infiltrated macrophage (CD68+) cells 
in the corneal stroma was counted in five randomly selected fields (×400) of the immunofluorescence-stained slides.
Notes: The number of infiltrating macrophages was analyzed by IBM SPSS (v 16.0; SPSS Inc, Chicago, IL). The data are presented as mean ± standard deviation (magnification: 
×100). Statistical significance is based on the difference when compared with the control; *P , 0.001.
Abbreviation: CI, confidence interval.
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Figure 7 Celastrol nanoparticles inhibit the expression of angiogenic genes. Corneas were harvested on day 6 after surgery, followed by messenger ribonucleic acid 
expression analysis using real-time reverse transcription-polymerase chain reaction. Normal corneas were used as the control. Messenger ribonucleic acid expression of 
vascular endothelial growth factor, matrix metalloproteinase 9, and monocyte chemoattractant protein 1 in the normal corneas were arbitrarily set as 1.0. The y-axis shows 
the mean of the relative messenger ribonucleic acid expression of a certain gene compared to the normal cornea gene. Celastrol nanoparticles decreased the expression 
of (A) vascular endothelial growth factor, (B) matrix metalloproteinase 9, and (C) monocyte chemoattractant protein 1 messenger ribonucleic acid in the cornea on day 6 
after surgery.
Notes: The data are presented as mean ± standard deviation. Statistical significance is based on the difference when compared with the control; *P , 0.001.
Abbreviations: CNPs, celastrol nanoparticles; MCP-1, monocyte chemoattractant protein 1; MMP-9, matrix metalloproteinase 9; VEGF, vascular endothelial growth factor.
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Figure 8 Celastrol nanoparticles inhibit the expression of angiogenic factor proteins in the cornea. Corneas were harvested on day 6 after surgery and the concentration of 
(A) vascular endothelial growth factor, (B) matrix metalloproteinase 9, and (C) monocyte chemoattractant protein 1 in the corneal tissue lysates were assessed by enzyme-
linked immunosorbent assay.
Notes: The data are presented as mean ± standard deviation of three independent experiments. Statistical significance is based on the difference when compared with the 
control; *P , 0.001.
Abbreviations: CNPs, celastrol nanoparticles; MCP-1, monocyte chemoattractant protein 1; MMP-9, matrix metalloproteinase 9; VEGF, vascular endothelial growth factor.
in MMP-9 (4.97-fold versus 2.35-fold) were observed in the 
CNP treatment group.
CNPs inhibit production  
of angiogenesis-related cytokines
The effects of CNPs on angiogenesis-related cytokines 
in the rat cornea were evaluated. The protein levels of 
VEGF, MMP-9, and MCP-1, as determined by ELISA 
were 125.04 ± 20.68 pg/mL, 15.37 ± 4.17 pg/mL, and 
3.81 ± 0.23 ng/mL, respectively, in the celastrol group 
and 3354.71 ± 98.17 pg/mL, 140.82 ± 8.06 pg/mL, and 
8.89 ± 0.25 ng/mL, respectively, in the control group on 
day 6 after surgery. As assayed by ELISA, VEGF, MMP-9, 
and MCP-1 production was significantly reduced by CNPs 
on day 6 after surgery (P , 0.001 for each; Figure 8).
Discussion
CNV is closely related to local inflammatory cell infiltra-
tion, and several chemokines and cytokines are involved 
in this process.29 Macrophages promote corneal angiogen-
esis by releasing several pro-angiogenic growth factors 
and matrix remodeling proteases. Because of the anti-
  inflammatory and anti-angiogenic activities of celastrol, 
it was speculated that celastrol mediates corneal angio-
genesis by modulating macrophage activity. However, the 
poor water solubility of celastrol restricted its application 
in vivo. In the present study, PEG-b-PCL nanopolymeric 
micelles were used as a celastrol delivery carrier and the 
effect of CNPs on the properties of HUVECs and suture-
induced CNV in rats was examined. The results indicate 
that CNPs significantly inhibited the proliferation and 
capillary structure formation of HUVECs and suppressed 
in vivo CNV by inhibiting macrophage infiltration, which 
in turn was accomplished by the downregulation of VEGF 
and MMP-9 in rat cornea.
PCL, as a hydrophobic polymer, is an ideal material 
for drug delivery and other applications.30,31 However, 
its low biocompatibility with soft tissue and rather slow 
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degradation restricts its further application. PEG – which 
is hydrophilic, nontoxic, and nonimmunogenic – can be 
attached to PCL to form PEG-b-PCL copolymers,32,33 which 
exhibit higher hydrophilicity and degradability, a more 
extended release, and better biocompatibility compared 
with the PCL homopolymer.34 Nanoformulated PEG-b-
PCL micelles as nanodrug delivery carriers have been used 
widely to improve the solubility of hydrophobic drugs.21,34,35 
The release behavior of PEG-b-PCL micelles has been 
studied extensively in vitro.36,37 In the present study, PEG-
b-PCL micelle drug release showed a typical two-phase 
release profile consisting of a relatively rapid release in 
the first stage followed by a slow and sustained release, 
which is in accordance with a previous report.37 PEG-b-PCL 
is also a safe candidate for a sustained ophthalmic drug 
delivery system, based on toxicity evaluations.38 Therefore, 
PEG-b-PCL nanopolymeric micelles were chosen as the 
celastrol delivery carrier to further study the effect of 
CNPs in preventing CNV in rats. In the present study, an 
absence of eye irritation, corneal epithelial defects, and 
other adverse complications with the use of the topical 
CNPs was observed.
The suture-induced CNV model has been extensively 
used to understand the mechanism of angiogenesis and to 
evaluate the anti-angiogenic activities of many drugs.25,26 
Some investigators have induced CNV by putting one stitch 
in the center of the cornea in rats, rabbits, or mice.4,25,39  
  Others have used more stitches and put them near the corneal 
limbus to induce more CNV .26,40 According to the authors’ 
unpublished observations, two stitches induced more CNV 
than one stitch placed the same distance from the corneal 
limbus. This finding supports those from previous reports. 
The distance of the two stitches from the limbus and the 
distance between the two stitches in the present study were 
in accordance with those of the corneal graft rejection model. 
This model probably best mimics angiogenesis in corneal 
graft rejections. In the present study, the two-stitch-induced 
CNV model was highly stable and reproducible, which 
makes it suitable for quantitative studies of CNV . It was also 
found that the effect of CNPs on CNV was superior with 
two subconjunctival administrations after surgery (day 0 and 
day 3) compared with only one administration at the same 
celastrol concentration. Therefore, two time points of sub-
conjunctival injection were chosen, day 0 and day 3 after 
suturing. The CNPs significantly inhibited CNV compared 
with the control group.
Celastrol, a quinone methide triterpenoid from the 
“Thunder of God Vine,” has various biological activities, 
including anti-angiogenesis, anti-inflammation, antitumor, 
and antioxidant.19,23,41 However, the process of angiogenesis 
is characterized by increased proliferation and the formation 
of capillary tubule-like structures by microvessel endothelial 
cells.3,4 In the present study, a dose-dependent inhibition 
of CNPs on HUVEC proliferation and tube formation was 
observed by WST-8 assays with an IC50 value of 6.875 µg/mL 
(celastrol loading content: 7.36%, concentration of celastrol: 
0.506 µg/mL) on EA.hy 926 cells. The IC50 value for free celas-
trol was 0.325 µg/mL. The lower potency of micelle-delivered 
celastrol can be due to a time-consuming celastrol release from 
micelles, which is consistent with in vitro celastrol release 
studies. The inhibition effect of CNPs on HUVEC viability 
had a major role in its anti-angiogenesis activity by reducing 
new blood vessel development. This is consistent with the 
previously observed anti-angiogenic effect of celastrol.23
Angiogenesis involves a complicated pathological 
process including numerous types of inflammatory cells 
and cytokines.5,6 Macrophages play a key role in CNV, 
tumor angiogenesis, and other pathological angiogenic 
processes.7,8,10 Macrophages modulate angiogenesis by 
secreting various angiogenesis-related mediators, such as 
cyclooxygenase 2, IL-1α, IL-8, and MMPs.7,42–44 The authors’ 
unpublished results suggest that macrophages could induce 
CNV by upregulating the expression of VEGF and MMP-9 in 
the cornea. In the present study, abundant macrophages 
were found in the sutured rat corneas, consistent with a 
previous study.11 Meanwhile, the control corneas expressed 
high levels of MCP-1 in mRNA and protein. MCP-1 is a 
potent macrophage-recruiting molecule. CNPs inhibited 
the expression of MCP-1 mRNA and protein and then sup-
pressed macrophage infiltration in the cornea. The inhibition 
of macrophage and inflammatory cells infiltration showed the 
anti-inflammatory activity of celastrol in this model.
VEGF is a specific vascular endothelial cell mitogen 
and the central regulator of angiogenesis in various physi-
ological and pathological conditions.45–48 In the present study, 
the expression of VEGF mRNA and protein were downregu-
lated by the CNPs in the rat cornea. The role of VEGF in 
angiogenesis may explain the major reason celastrol inhibited 
CNV in this model. The downregulation of VEGF mRNA 
and protein in the cornea demonstrated the anti-angiogenic 
activities of CNPs. Degradation of the extracellular matrix 
is an important process in angiogenesis. MMPs are 
important factors that degrade the extracellular matrix.49,50 
MMP-9, also known as gelatin B, plays a crucial role in 
degrading extracellular matrix and basement membrane 
during angiogenesis and organizational restructuring.51 
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  Celastrol inhibits the migration and invasion of human 
breast carcinoma cells by downregulating MMP-9 expres-
sion in MCF-7 human breast cancer cells.52 In the present 
study, CNPs inhibited macrophage infiltration and accompa-
nied the downregulation of MMP-9 at both the mRNA and 
protein levels in corneal tissue. This suggests that celastrol 
may block the development and progression of angiogen-
esis by altering extracellular matrix degradation. Celastrol 
can inhibit the production of TNF-α, IL-6, and IL-1β in 
human monocytes, mouse macrophages, and microglial 
cells.16,53,54 However, results from the present study suggest 
that celastrol may suppress CNV by inhibiting macrophage 
infiltration and decreasing the expression of VEGF and 
MMP-9 in the cornea.
Conclusion
According to the authors’ findings, two stitches can induce 
CNV in rats. This rat model is a highly stable, reproducible 
model and suitable for quantitative studies of CNV . PEG-b-PCL 
nanopolymeric micelles improve the water solubility of celas-
trol, a traditional Chinese herbal medicine. Celastrol release 
research shows a typical two-phase release profile containing 
a burst release followed by a sustained release.
Celastrol-loaded PEG-b-PCL nanopolymeric micelles 
inhibited the capillary structure formation and proliferation 
of HUVECs in a dose-dependent manner. CNPs suppress 
suture-induced CNV by inhibiting macrophage infiltration 
and reducing the expression of VEGF and MMP-9 at both the 
mRNA and protein level in the rat cornea. Celastrol shows 
potent anti-inflammatory and anti-angiogenic activities in this 
model. However, further studies are required to clarify the 
long-term side effects of celastrol on eyes and the signaling 
pathway utilized by celastrol to inhibit CNV .
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